<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615160</url>
  </required_header>
  <id_info>
    <org_study_id>UKSH A-105</org_study_id>
    <secondary_id>EudraCT No. 2005-002192-32</secondary_id>
    <nct_id>NCT00615160</nct_id>
  </id_info>
  <brief_title>PTK/ZK in Disseminated Malignant Melanoma</brief_title>
  <official_title>Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Weichenthal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of PTK-ZK on metastatic melanoma either as a single agent treatment&#xD;
      or in combination with standard chemotherapy according to RECIST criteria. Further to&#xD;
      evaluate the safety and tolerability of PTK-ZK in patients with metastatic melanoma either as&#xD;
      a single agent treatment or in combination with standard chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open-label, parallel-group phase II study to evaluate the&#xD;
      efficacy and safety of PTK-ZK in the treatment of patients with metastatic malignant melanoma&#xD;
      who do not qualify for surgical resection:&#xD;
&#xD;
        -  progressive locoregionary disease not to be controlled by surgical measures&#xD;
&#xD;
        -  distant metastasis other than brain metastasis not eligible for surgical resection or&#xD;
           radiotherapy All patients will be treated with PTK-ZK 1250mg administered orally once a&#xD;
           day for treatment cycles of 28 days. In case of unacceptable toxicity the dose can be&#xD;
           reduced to 1000 mg and further on to 750 mg daily.&#xD;
&#xD;
      Patients in Arm B additionally receive intravenous DTIC 850mg/m² on day 1 of each cycle.&#xD;
&#xD;
      After informed consent is given by the patient a biopsy from a metastasis should be taken&#xD;
      before the first intake of study medication and at the end of cycle 2 to specify markers of&#xD;
      angiogenesis and MVD (Micro vessel density).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Substance was withdrawn from further development.&#xD;
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response defined by RECIST criteria</measure>
    <time_frame>8 week response rate</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity and safety</measure>
    <time_frame>continuously</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control as defined by the number of patients with objective tumor response or tumor stabilization according to RECIST criteria</measure>
    <time_frame>Best response during time of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time of progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ C30)</measure>
    <time_frame>During active treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTK787/ZK 222584</intervention_name>
    <description>PTK-ZK capsules taken orally with a daily flat dose of 1250 mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Dacarbazine 850 mg/m² on day 1 q4w</description>
    <arm_group_label>B</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed nonresectable metastatic melanoma Stage III or IV (AJCC 2002)&#xD;
             including patients with unknown primary melanoma,&#xD;
&#xD;
          -  Progressive disease, defined as an increase of tumour volume according to RECIST&#xD;
             criteria, within the last 6 months,&#xD;
&#xD;
          -  Fulfilling the minimum RECIST requirements for evaluation of tumor response,&#xD;
&#xD;
          -  At least two cutaneous or soft tissue lesions that can be biopsised prior to and after&#xD;
             treatment, respectively,&#xD;
&#xD;
          -  Able to undergo either contrast-enhanced CT scan or contrast-enhanced MRI scan for&#xD;
             tumor assessment,&#xD;
&#xD;
          -  Life expectancy greater than 3 months,&#xD;
&#xD;
          -  ECOG performance status &lt;2,&#xD;
&#xD;
          -  Age &gt; 18 years,&#xD;
&#xD;
          -  Able to swallow and retain intact investigational drug tablets,&#xD;
&#xD;
          -  Willingness and ability to adhere to the study requirements as outlined in the&#xD;
             protocol,&#xD;
&#xD;
          -  Agreement to use a highly effective method of birth control throughout the study&#xD;
             period and 3 months thereafter for sexually active males and females of childbearing&#xD;
             potential. Barrier contraceptives must be used throughout the trial. Oral,&#xD;
             implantable, or injectable contraceptives may be affected by cytochrome P450&#xD;
             interactions, and are therefore not considered effective for this study.&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  One or more previous systemic therapies for metastatic melanoma, excluding prior&#xD;
             systemic therapy given for high-risk primary tumor, lymph node metastasis, or other&#xD;
             regional (AJCC stage III) disease spread as postoperative adjuvant therapy.&#xD;
&#xD;
          -  Anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy, and hormone&#xD;
             therapy) delivered within 4 weeks prior to the 1st dose of study drug, and 2 weeks&#xD;
             prior for palliative &quot;spot&quot; radiotherapy to bone metastases),&#xD;
&#xD;
          -  History of uveal melanoma,&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding. Women of childbearing potential&#xD;
             must have a negative serum pregnancy test 48 hours prior to administration of study&#xD;
             treatment.&#xD;
&#xD;
          -  Impaired organ and bone marrow function defined as one or more of the following:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1,500/µl,&#xD;
&#xD;
          -  Platelets &lt;100,000/µl,&#xD;
&#xD;
          -  Total bilirubin &gt;1.5 x ULN,&#xD;
&#xD;
          -  ASAT (SGOT)/ALAT (SGPT) &gt; 3x ULN (5x if liver metastases are present)&#xD;
&#xD;
          -  History or presence of central nervous system (CNS) disease (i.e., primary brain&#xD;
             tumor, malignant seizures, CNS metastases or carcinomatous meningitis)&#xD;
&#xD;
          -  Another malignancy in the 5 years prior to enrollment other than non melanoma skin&#xD;
             cancer, or cervix carcinoma in situ,&#xD;
&#xD;
          -  Major Surgery &lt; 10 days prior to the start of study treatment&#xD;
&#xD;
          -  Inadequate recovery from previous surgery, radiation, chemo-, biologic or&#xD;
             immunotherapy&#xD;
&#xD;
          -  Ongoing effects from previous investigational drug studies or concomitant&#xD;
             participation in other investigational drug studies&#xD;
&#xD;
          -  Prior use of PTK-ZK or other VGEF receptor antagonists,&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to PTK-ZK, or patients who have known hypersensitivity to the study&#xD;
             medication&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of PTK/ZK (i.e., ulcerative disease, uncontrolled nausea,&#xD;
             vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow&#xD;
             the tablets).&#xD;
&#xD;
          -  Myocardial infarction ≤ 6 months prior to randomization&#xD;
&#xD;
          -  Acute or chronic liver disease (i.e., hepatitis, cirrhosis)&#xD;
&#xD;
          -  Uncontrolled high blood pressure, history of labile hypertension, or history of poor&#xD;
             compliance with an antihypertensive regimen&#xD;
&#xD;
          -  Chronic renal disease, i.e. Creatinine &gt;1.5 x upper limit of normal (ULN) OR&#xD;
             Proteinuria based on dip stick reading positive &gt; +1 OR if the dip stick result is +1,&#xD;
             total urinary protein &gt; 500 mg and measured creatinine clearance &lt; 50 ml/min from a&#xD;
             24-hour urine collection Haemoglobin &lt; 9 g/dL (patients may be transfused to achieve&#xD;
             Hb &gt; 9 g/dL)&#xD;
&#xD;
        Other uncontrolled concomitant condition, including but not limited to:&#xD;
&#xD;
          -  ongoing or active infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, serious uncontrolled cardiac arrhythmia, uncontrolled diabetes, seizure&#xD;
             disorder&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements, or other conditions that compromise the patient's ability to understand&#xD;
             the patient information, to give informed consent, to comply with the trial protocol,&#xD;
             or to complete the study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection,&#xD;
&#xD;
          -  Prior enrollment into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Weichenthal, MD</last_name>
    <role>Study Director</role>
    <affiliation>UK-SH Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dpt. of Dermatology, University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. of Dermatology, University of Frankfurt</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. of Dermatology; UK-SH Campus Kiel, Germany</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. of Dermatology, University of Cologne</name>
      <address>
        <city>Koeln</city>
        <zip>D-50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Michael Weichenthal</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Metastatic melanoma</keyword>
  <keyword>anti angiogenetic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

